Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Friede

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Vaccines|June 25, 2026
From Global Insights to Local Action: Bridging Vaccine Design and Manufacturing Gaps in H5N1 Pandemic ReadinessMaría Alicia Delfino, Jimena Borgo, Luciano Chaneton, et al.
Colloids and Surfaces. B, Biointerfaces|September 15, 2009
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulationsRyan C Anderson, Christopher B Fox, Timothy S Dutill, et al.
Vaccine|January 17, 2018
Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22-23 March 2017M Teresa Aguado, Jane Barratt, John R Beard, et al.
Expert Opinion on Drug Delivery|January 17, 2023
Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilitiesTiziana Scarnà, Marion Menozzi-Arnaud, Martin Friede, et al.
Vaccine|February 6, 2018
Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristicsJohan Vekemans, Vasee Moorthy, Martin Friede, et al.
Plos One|February 8, 2011
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvantRhea N Coler, Sylvie Bertholet, Magdalini Moutaftsi, et al.
Vaccines|February 24, 2024
A Practical Guide to Full Value of Vaccine AssessmentsCaroline Trotter, Birgitte Giersing, Ann Lindstrand, et al.
The Lancet. Infectious Diseases|May 24, 2017
Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trialPunnee Pitisuttithum, Kobporn Boonnak, Supat Chamnanchanunt, et al.
NPJ Vaccines|May 16, 2020
H7N9 influenza split vaccine with SWE oil-in-water adjuvant greatly enhances cross-reactive humoral immunity and protection against severe pneumonia in ferretsJørgen de Jonge, Harry van Dijken, Femke de Heij, et al.
Plos One|October 18, 2022
Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trialTazio Vanni, Beatriz C Thomé, Erin Sparrow, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Vaccines|June 25, 2026
From Global Insights to Local Action: Bridging Vaccine Design and Manufacturing Gaps in H5N1 Pandemic ReadinessMaría Alicia Delfino, Jimena Borgo, Luciano Chaneton, et al.
Colloids and Surfaces. B, Biointerfaces|September 15, 2009
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulationsRyan C Anderson, Christopher B Fox, Timothy S Dutill, et al.
Vaccine|January 17, 2018
Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22-23 March 2017M Teresa Aguado, Jane Barratt, John R Beard, et al.
Expert Opinion on Drug Delivery|January 17, 2023
Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilitiesTiziana Scarnà, Marion Menozzi-Arnaud, Martin Friede, et al.
Vaccine|February 6, 2018
Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristicsJohan Vekemans, Vasee Moorthy, Martin Friede, et al.
Plos One|February 8, 2011
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvantRhea N Coler, Sylvie Bertholet, Magdalini Moutaftsi, et al.
Vaccines|February 24, 2024
A Practical Guide to Full Value of Vaccine AssessmentsCaroline Trotter, Birgitte Giersing, Ann Lindstrand, et al.
The Lancet. Infectious Diseases|May 24, 2017
Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trialPunnee Pitisuttithum, Kobporn Boonnak, Supat Chamnanchanunt, et al.
NPJ Vaccines|May 16, 2020
H7N9 influenza split vaccine with SWE oil-in-water adjuvant greatly enhances cross-reactive humoral immunity and protection against severe pneumonia in ferretsJørgen de Jonge, Harry van Dijken, Femke de Heij, et al.
Plos One|October 18, 2022
Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trialTazio Vanni, Beatriz C Thomé, Erin Sparrow, et al.
Pageof 4